Boston Scientific Corporation
Financials
Valuation Metrics
Boston Scientific Corporation's Market Cap is $64.26B. At end of 2025 it was $141.38B. Ranked #273 of 3,116 in US market (top 9%), #199 of 1,644 on NYSE (top 12%), #15 of 203 in Health Care Equipment & Services (top 7%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $64.26B | US#273/3,116 Sec#15/203 |
| Revenue | $21.00B | US#307/3,116 Sec#21/203 |
| Net Income | $3.67B | US#201/3,116 Sec#12/203 |
| Total Assets | $45.22B | US#349/3,116 Sec#17/203 |
| Net Assets | $24.93B | US#194/3,116 Sec#9/203 |
| Employees | 59,000 | US#222/3,116 Sec#19/203 |
| Value | ||
| P/E | 17.52x | US#897/3,116 Sec#16/203 |
| P/B | 2.58x | US#1,528/3,116 Sec#69/203 |
| PEG | 0.38x | US#473/3,116 Sec#17/203 |
| P/S | 3.06x | US#1,669/3,116 Sec#111/203 |
| EV/EBITDA | 13.44x | US#1,237/3,116 Sec#39/203 |
| FCF Yield | 5.64% | US#1,201/3,116 Sec#48/203 |
| Profitability | ||
| ROE | 14.71% | US#908/3,116 Sec#43/203 |
| ROA | 8.11% | US#646/3,116 Sec#38/203 |
| Op. Margin | 21.46% | US#818/3,116 Sec#23/203 |
| Revenue Growth | 13.53% | US#987/3,116 Sec#69/203 |
| Earnings Growth | 46.56% | US#521/3,116 Sec#28/203 |
| Financial Health | ||
| Debt Ratio | 80.40% | US#893/3,116 Sec#89/203 |
| Total Debt | $12.62B | US#349/3,116 Sec#18/203 |
| FCF | $3.63B | US#221/3,116 Sec#16/203 |
| Cash | $539M | US#1,026/3,116 Sec#56/203 |
| Current Ratio | 1.24x | US#1,947/3,116 Sec#166/203 |
| Net Debt/EBITDA | 2.13x | US#1,370/3,116 Sec#85/203 |
| Performance | ||
| 1Y Return | -55.98% | US#2,954/3,116 Sec#194/203 |
| 1M Return | 4.08% | US#2,128/3,116 Sec#164/203 |
| From 52W High | -58.03% | US#2,861/3,116 Sec#191/203 |
| 1Y MDD | -60.39% | US#2,727/3,116 Sec#170/203 |
| Trading | ||
| Volume | 18,098,614 shares | US#49/3,116 Sec#1/203 |
| Trading Value | $788M | US#63/3,116 Sec#3/203 |
| Per Share | ||
| EPS | $2.53 | US#1,172/3,116 Sec#62/203 |
| BPS | $17.20 | US#1,396/3,116 Sec#79/203 |
Company Info
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.